Can-fite Biopharma Ltd. key statistics and ratios

In fiscal 2025, Can-fite Biopharma Ltd. had return on equity of -178.2% and a net margin of -2426.7%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Can-fite Biopharma Ltd.: financial ratios, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Net margin	−172.0%	−621.3%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%
Return on equity	—	—	—	−123.3%	−107.9%	−142.5%	−134.9%	−178.2%
Return on assets	—	−154.5%	−163.2%	−84.7%	−68.9%	−79.2%	−82.5%	−105.5%
R&D as % of revenue	159.0%	540.2%	>999%	>999%	958.4%	805.2%	854.2%	>999%
SG&A as % of revenue	—	—	41.5%	54.6%	32.5%	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 2 checks passed · December 31, 2025

What it owns · $10m

Short-term assets $9mLonger-term assets $0m

What it owes, and who funded it · $8m

Short-term liabilities $3mShareholders' equity $6m

Short-term assets cover short-term liabilities $9m of assets due within a year against $3m of liabilities due within a year.
Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$10m against $284,000 of interest.

From Can-fite Biopharma Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CANF vs CRVO CANF vs CRDF CANF vs CLNN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Can-fite Biopharma Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Can-fite Biopharma Ltd.